Luye Pharma Group Ltd. 2186
HKEX · Hong Kong SAR China · Health Technology
HKD 1.82-0.07 (-3.96%)
Market open· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
PRINCETON, N.J., September 23, 2026--Study Published Shows Potential Benefit of Alternative Maintenance Dosing Strategies for Paliperidone Palmitate in Treatment of Schizophrenia
As global markets navigate a landscape marked by U.S. economic resilience and mixed performances across major indices, investors are increasingly turning their attention to Asia, where small-cap stocks offer intriguing opportunities amid broader market fluctuations. In this context, identifying companies with strong fundamentals becomes crucial, as these attributes can provide stability and growth potential in an environment characterized by shifting economic dynamics and evolving sector trends.
Luye Pharma Group (SEHK:2186) shares have seen moderate movement over the past month. Investors are keeping a close eye on the company’s performance data and broader trends impacting the pharmaceutical sector in Hong Kong. See our latest analysis for Luye Pharma Group. Luye Pharma Group’s share price has shown some impressive momentum this year, climbing 61.79% year-to-date. That strength stands out, even though the most recent 30-day share price return was negative at -6.03%. Over the past...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.